Print Friendly, PDF & Email

NCT/Study#

NCT04268706 /

TESSCAR001

A Phase 2 Multi-Center Study Evaluating The Safety And Efficacy Of CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T) In Adult And Pediatric Patients With Relapsed Or Refractory CD30 Positive Classical Hodgkin Lymphoma (CHARIOT TESSCAR001)

DISEASE GROUP:
Lymphoma
current phase:
Phase II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: